These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
250 related articles for article (PubMed ID: 31755366)
1. Targeting DNA methylation for treating triple-negative breast cancer. Yu J; Zayas J; Qin B; Wang L Pharmacogenomics; 2019 Nov; 20(16):1151-1157. PubMed ID: 31755366 [TBL] [Abstract][Full Text] [Related]
2. DNA methyltransferase expression in triple-negative breast cancer predicts sensitivity to decitabine. Yu J; Qin B; Moyer AM; Nowsheen S; Liu T; Qin S; Zhuang Y; Liu D; Lu SW; Kalari KR; Visscher DW; Copland JA; McLaughlin SA; Moreno-Aspitia A; Northfelt DW; Gray RJ; Lou Z; Suman VJ; Weinshilboum R; Boughey JC; Goetz MP; Wang L J Clin Invest; 2018 Jun; 128(6):2376-2388. PubMed ID: 29708513 [TBL] [Abstract][Full Text] [Related]
3. The frequency of CpG and non-CpG methylation of Notch3 gene promoter determines its expression levels in breast cancer cells. Xiao W; Liu X; Niu X; Li C; Guo Y; Tan J; Xiong W; Fan L; Li Y Exp Cell Res; 2020 Jan; 386(2):111743. PubMed ID: 31770532 [TBL] [Abstract][Full Text] [Related]
4. Curcumin induces re‑expression of BRCA1 and suppression of γ synuclein by modulating DNA promoter methylation in breast cancer cell lines. Al-Yousef N; Shinwari Z; Al-Shahrani B; Al-Showimi M; Al-Moghrabi N Oncol Rep; 2020 Mar; 43(3):827-838. PubMed ID: 32020216 [TBL] [Abstract][Full Text] [Related]
5. Pharmacologic reversion of epigenetic silencing of the PRKD1 promoter blocks breast tumor cell invasion and metastasis. Borges S; Döppler H; Perez EA; Andorfer CA; Sun Z; Anastasiadis PZ; Thompson E; Geiger XJ; Storz P Breast Cancer Res; 2013 Aug; 15(2):R66. PubMed ID: 23971832 [TBL] [Abstract][Full Text] [Related]
6. Inhibition of DNMT1 and ERRα crosstalk suppresses breast cancer via derepression of IRF4. Vernier M; McGuirk S; Dufour CR; Wan L; Audet-Walsh E; St-Pierre J; Giguère V Oncogene; 2020 Oct; 39(41):6406-6420. PubMed ID: 32855526 [TBL] [Abstract][Full Text] [Related]
7. DNMT1: A key drug target in triple-negative breast cancer. Wong KK Semin Cancer Biol; 2021 Jul; 72():198-213. PubMed ID: 32461152 [TBL] [Abstract][Full Text] [Related]
8. Epigenetic Regulation of CDH1 Is Altered after HOXB7-Silencing in MDA-MB-468 Triple-Negative Breast Cancer Cells. Paço A; Leitão-Castro J; Freitas R Genes (Basel); 2021 Oct; 12(10):. PubMed ID: 34680970 [TBL] [Abstract][Full Text] [Related]
9. Activation of silenced tumor suppressor genes in prostate cancer cells by a novel energy restriction-mimetic agent. Lin HY; Kuo YC; Weng YI; Lai IL; Huang TH; Lin SP; Niu DM; Chen CS Prostate; 2012 Dec; 72(16):1767-78. PubMed ID: 22539223 [TBL] [Abstract][Full Text] [Related]
10. Antineoplastic activity of the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine in anaplastic large cell lymphoma. Hassler MR; Klisaroska A; Kollmann K; Steiner I; Bilban M; Schiefer AI; Sexl V; Egger G Biochimie; 2012 Nov; 94(11):2297-307. PubMed ID: 22687603 [TBL] [Abstract][Full Text] [Related]
11. Promoter methylation status of tumor suppressor genes and inhibition of expression of DNA methyltransferase 1 in non-small cell lung cancer. Liu B; Song J; Luan J; Sun X; Bai J; Wang H; Li A; Zhang L; Feng X; Du Z Exp Biol Med (Maywood); 2016 Aug; 241(14):1531-9. PubMed ID: 27190263 [TBL] [Abstract][Full Text] [Related]
12. Epigenetic reprogramming of epithelial mesenchymal transition in triple negative breast cancer cells with DNA methyltransferase and histone deacetylase inhibitors. Su Y; Hopfinger NR; Nguyen TD; Pogash TJ; Santucci-Pereira J; Russo J J Exp Clin Cancer Res; 2018 Dec; 37(1):314. PubMed ID: 30547810 [TBL] [Abstract][Full Text] [Related]
13. Induction of the estrogen receptor by ablation of DNMT1 in ER-negative breast cancer cells. Adams PD; Cairns P Cancer Biol Ther; 2003; 2(5):557-8. PubMed ID: 14614326 [No Abstract] [Full Text] [Related]
14. Higher levels of TIMP-1 expression are associated with a poor prognosis in triple-negative breast cancer. Cheng G; Fan X; Hao M; Wang J; Zhou X; Sun X Mol Cancer; 2016 Apr; 15(1):30. PubMed ID: 27130446 [TBL] [Abstract][Full Text] [Related]
15. Reexpression of tumor suppressor, sFRP1, leads to antitumor synergy of combined HDAC and methyltransferase inhibitors in chemoresistant cancers. Cooper SJ; von Roemeling CA; Kang KH; Marlow LA; Grebe SK; Menefee ME; Tun HW; Colon-Otero G; Perez EA; Copland JA Mol Cancer Ther; 2012 Oct; 11(10):2105-15. PubMed ID: 22826467 [TBL] [Abstract][Full Text] [Related]